Bicycle Therapeutics (BCYC) Deferred Taxes (2022 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Deferred Taxes came in at $326000.0 in Q2 2026, up 198.49% YoY from $109216.6 in Q2 2025, and up 235.27% on a QoQ basis from -$241000.0 in Q1 2026.
Bicycle Therapeutics (BCYC) Deferred Taxes (2022 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 5 years of Deferred Taxes data on file, last reported at $326000.0 in Q2 2026.
- Quarterly Deferred Taxes rose 198.49% year-over-year to $326000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $428000.0 (up 107.14% YoY) and the FY2025 annual result came in at -$1.3 million, up 75.05% from the prior year.
- Deferred Taxes rose to $326000.0 in Q2 2026, from -$241000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $7.3 million in Q3 2023 to a low of -$3.3 million in Q3 2024.
- A 5-year average of -$450833.3 and a median of -$757500.0 in 2022 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2023 — Deferred Taxes jumped 810.06% — and 2024, when it tumbled 266.67%.
- Tracing BCYC's Deferred Taxes over 5 years: stood at -$2.3 million in 2022, then surged by 87.93% to -$282000.0 in 2023, then plunged by 266.67% to -$1.0 million in 2024, then surged by 137.62% to $389000.0 in 2025, then declined by 16.2% to $326000.0 in 2026.
- The last three Deferred Taxes figures came in at $326000.0 (Q2 2026), -$241000.0 (Q1 2026), and $389000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 326,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 326,000.00 |
| Mar 31, 2026 | -241,000.00 |
| Dec 31, 2025 | 389,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | -331,000.00 |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | 420,000.00 |
| Sep 30, 2024 | -3.32 Mn |
| Jun 30, 2024 | -110,000.00 |
| Mar 31, 2024 | -767,000.00 |
| Dec 31, 2023 | -1.08 Mn |
| Sep 30, 2023 | 7.27 Mn |
| Jun 30, 2023 | -1.58 Mn |
| Mar 31, 2023 | -2.11 Mn |
| Dec 31, 2022 | -2.34 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -868,000.00 |
| Mar 31, 2022 | -748,000.00 |